Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer.

Authors:
Ming Bai
Ming Bai
Fourth Military Medical University
China
Na Song
Na Song
a Institute of Evolution and Marine Biodiversity
China
Dr. Xiaofang Che, MD, PhD
Dr. Xiaofang Che, MD, PhD
China Medical University
Shenyang, Liaoning | China
Xiaoxun Wang
Xiaoxun Wang
Anhui Key Laboratory of Chemo-Biosensing; Key Laboratory of Functional Molecular Solids
Xiujuan Qu
Xiujuan Qu
The First Hospital of China Medical University
Shenyang Shi | China
Yunpeng Liu
Yunpeng Liu
The First Hospital of China Medical University
China

Cell Biol Int 2018 Jul 14;42(7):781-793. Epub 2018 May 14.

Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.

The ATM and Rad3-related (ATR)/checkpoint kinase 1 (Chk1) pathway plays a pivotal role in DNA damage sensor and modulating homologous recombination. Recently, emerging evidence demonstrated that Chk1 phosphorylation was associated with chemotherapy and radiotherapy resistance. In this study, we explored the effect of ATR/Chk1 pathway on regulating lapatinib sensitivity in human epidermal growth factor receptor-2 (HER2)-positive gastric cancer cell lines. We selected two HER2-positive gastric cancer cell lines, and NCI-N87 cells exhibited higher sensitivity than MKN7 cells. Application of lapatinib inhibited phosphorylated HER2 and EGFR and the formation of epidermal growth factor receptor (EGFR)/HER2 complex in both cells. In NCI-N87 cells, lapatinib induced G1 arrest and reduced Chk1 phosphorylation through inhibiting the expression of DNA topoisomerase 2-binding protein 1 (TopBP1). While in MKN7 cells, no significant cell cycle transition was found and phosphorylated Chk1 was mildly upregulated. Inhibition of Chk1 phosphorylation enhanced the lapatinib sensitivity of MKN7 cells, which was shown by potentiated anti-proliferative effect, G1 arrest, downregulation of phosphorylated AKT and ERK along with aggravated DNA damage. In addition, increased Chk1 phosphorylation in NCI-N87 cells attenuated lapatinib-induced anti-proliferative effect and G1 arrest, and abrogated reduced phosphorylated AKT and ERK. Taken together, our study provides a novel mechanism for regulating lapatinib sensitivity in HER2 positive gastric cancer cells, suggesting a new strategy in clinical treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cbin.10922DOI Listing
July 2018
7 Reads

Publication Analysis

Top Keywords

gastric cancer
16
chk1 phosphorylation
16
mkn7 cells
12
her2-positive gastric
12
lapatinib sensitivity
12
nci-n87 cells
12
cell lines
8
regulating lapatinib
8
growth factor
8
anti-proliferative arrest
8
akt erk
8
sensitivity mkn7
8
dna damage
8
phosphorylated akt
8
cancer cell
8
cells
8
epidermal growth
8
chk1
7
lapatinib
6
sensitivity
5

Similar Publications

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.

Cancer Lett 2008 Dec 6;272(2):296-306. Epub 2008 Sep 6.

Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Republic of Korea.

HER2 overexpression is observed in 5-25% of gastric cancers. Lapatinib is a dual inhibitor of the epidermal growth factor receptor and HER2 tyrosine kinase. We examined the antitumor effect of lapatinib in gastric cancer cell lines. Read More

View Article
December 2008

MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.

Mol Cancer Ther 2012 Mar 11;11(3):660-9. Epub 2012 Jan 11.

Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

HER2 amplification is found in more than 15% of gastric cancers and is associated with poor clinical outcome. Lapatinib, a dual HER2 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has shown promising in vitro results in treating HER2(+) cancer cells. However, several studies have shown that activation of alternative receptor tyrosine kinases can mediate resistance to HER-targeted therapy. Read More

View Article
March 2012

A novel function of hepatocyte growth factor in the activation of checkpoint kinase 1 phosphorylation in colon cancer cells.

Mol Cell Biochem 2017 Dec 1;436(1-2):29-38. Epub 2017 Jun 1.

Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, People's Republic of China.

The ATR/checkpoint kinase 1 (Chk1) pathway plays an essential role in modulating the DNA damage response and homologous recombination. Particularly, Chk1 phosphorylation is related to cancer prognosis and therapeutic resistance. Some receptor tyrosine kinases participate in the regulation of Chk1 phosphorylation; however, the effect of hepatocyte growth factor (HGF) on Chk1 phosphorylation is unknown. Read More

View Article
December 2017

Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.

Oncogene 2014 Jun 22;33(25):3334-41. Epub 2013 Jul 22.

1] Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea [2] Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea [3] WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.

Human epidermal growth factor receptor 2 (HER2)-directed treatment using trastuzumab has shown clinical benefit in HER2-positive gastric cancer. Clinical trials using lapatinib in HER2-positive gastric cancer are also currently underway. As with other molecularly targeted agents, the emergence of acquired resistance to HER2-directed treatment is an imminent therapeutic problem for HER2-positive gastric cancer. Read More

View Article
June 2014